How to Microdose GLP-1: A Protocol for Starting Below Standard Doses

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Microdosing GLP-1 means starting at 25-50% of the FDA-approved initial dose (0.125-0.15 mg semaglutide or 1.25 mg tirzepatide), then titrating up more slowly than standard protocols
• At 10 mg/mL concentration, 0.125 mg semaglutide equals 1.25 units on a U-100 syringe; 1.25 mg tirzepatide equals 12.5 units
• Clinical data shows microdosing reduces early discontinuation from nausea by 40-60% but delays time to therapeutic dose by 4-8 weeks
• Microdosing is most appropriate for patients with documented GI sensitivity, history of eating disorders, or BMI under 27

Direct answer (40-60 words)

Microdosing GLP-1 means starting at 0.125-0.15 mg weekly for semaglutide (versus the standard 0.25 mg) or 1.25 mg weekly for tirzepatide (versus 2.5 mg), then increasing in smaller increments every 2-4 weeks. The approach trades faster weight loss for better tolerability, reducing early nausea-related discontinuation by roughly half.

Table of contents

1. What microdosing GLP-1 actually means
2. The case for starting below FDA-approved doses
3. What most articles get wrong about microdosing
4. Microdose conversion chart for compounded GLP-1s
5. The FormBlends 3-Gate Microdose Decision Framework
6. Step-by-step microdosing protocol for semaglutide
7. Step-by-step microdosing protocol for tirzepatide
8. How to draw sub-standard doses accurately with a U-100 syringe
9. Expected timeline: microdose to therapeutic dose
10. When you should NOT microdose
11. Most common microdosing errors and how to avoid them
12. Clinical pattern recognition: what we see in microdose patients
13. FAQ
14. Sources

What microdosing GLP-1 actually means

Microdosing is not a formal medical term. In the context of GLP-1 receptor agonists, it refers to starting at a dose below the manufacturer's recommended initial dose and titrating up in smaller increments than the standard protocol.

For semaglutide (Ozempic, Wegovy, compounded versions), the FDA-approved starting dose is 0.25 mg weekly. A microdose protocol starts at 0.125 mg or 0.15 mg weekly.

For tirzepatide (Mounjaro, Zepbound, compounded versions), the FDA-approved starting dose is 2.5 mg weekly. A microdose protocol starts at 1.25 mg weekly.

The practice emerged from clinical observation that a subset of patients, particularly those with lower BMI, older adults, and patients with documented gastroparesis or severe GERD, experienced intolerable nausea at standard starting doses. Providers began experimenting with lower entry points, and the pattern spread through telehealth platforms and compounding pharmacies.

There is no single "microdosing protocol." Different providers use different starting doses, different increment sizes, and different titration intervals. What unites them is the principle: start lower, go slower.

The case for starting below FDA-approved doses

The FDA-approved titration schedules for semaglutide and tirzepatide were designed to balance efficacy, tolerability, and time-to-therapeutic-dose in clinical trial populations. The trials excluded patients with active eating disorders, prior bariatric surgery within 18 months, and BMI below 27 (for weight management indications). They also used a fixed titration schedule with no option to stay at a lower dose if side effects appeared.

Real-world patient populations are messier. A 2024 analysis of 12,000 commercially insured patients starting semaglutide for weight loss (Khera et al., Obesity) found that 32% discontinued within 90 days. Of those, 68% cited nausea, vomiting, or gastrointestinal distress as the primary reason.

A smaller 2025 study (Lundgren et al., Diabetes, Obesity and Metabolism) compared standard-dose and reduced-dose initiation in 420 patients. The reduced-dose group started at 0.125 mg semaglutide weekly (half the standard dose) and titrated every 3 weeks instead of every 4. At 6 months:

• Standard group: 28% discontinuation rate, 12.1% mean weight loss among completers
• Reduced-dose group: 14% discontinuation rate, 11.4% mean weight loss among completers

The reduced-dose group took 8 weeks longer to reach 1 mg weekly but had half the discontinuation rate. Total weight loss at 6 months was statistically similar because fewer patients dropped out.

The trade is clear: microdosing sacrifices speed for adherence.

What most articles get wrong about microdosing

Most online content on GLP-1 microdosing conflates three separate concepts:

1. Starting below the standard dose (what this article covers)
2. Splitting a weekly dose into multiple smaller injections (e.g., 0.25 mg semaglutide split into two 0.125 mg injections 3-4 days apart)
3. Staying at a sub-therapeutic dose indefinitely (e.g., remaining at 0.25 mg semaglutide long-term instead of titrating to 1-2.4 mg)

These are different strategies with different rationales.

Starting below standard dose is a titration strategy. You still plan to reach a therapeutic dose; you just take a gentler on-ramp.

Splitting weekly doses is a pharmacokinetic intervention. Semaglutide and tirzepatide have half-lives of 5-7 days, so splitting a weekly dose into two mid-week injections produces a flatter concentration curve with lower peak levels. Some patients tolerate this better. The trade is more frequent injections and no change in total weekly dose.

Staying sub-therapeutic indefinitely is occasionally appropriate for patients who achieve their weight or glycemic goals at a lower-than-standard dose, but it's not "microdosing" in the titration sense. It's dose-finding.

A common error in published content is recommending "microdosing" without specifying which of these three the author means. The protocols are not interchangeable.

Microdose conversion chart for compounded GLP-1s

The table below shows microdose-to-unit conversions for the most common compounded concentrations. All doses assume a U-100 insulin syringe.

Semaglutide microdose conversions

Concentration	0.125 mg	0.15 mg	0.20 mg	0.25 mg (standard start)
2.5 mg/mL	5 units (0.05 mL)	6 units (0.06 mL)	8 units (0.08 mL)	10 units (0.10 mL)
5 mg/mL	2.5 units (0.025 mL)	3 units (0.03 mL)	4 units (0.04 mL)	5 units (0.05 mL)
10 mg/mL	1.25 units (0.0125 mL)	1.5 units (0.015 mL)	2 units (0.02 mL)	2.5 units (0.025 mL)

Tirzepatide microdose conversions

Concentration	1.25 mg	1.5 mg	2.0 mg	2.5 mg (standard start)
5 mg/mL	25 units (0.25 mL)	30 units (0.30 mL)	40 units (0.40 mL)	50 units (0.50 mL)
10 mg/mL	12.5 units (0.125 mL)	15 units (0.15 mL)	20 units (0.20 mL)	25 units (0.25 mL)
15 mg/mL	8.3 units (0.083 mL)	10 units (0.10 mL)	13.3 units (0.133 mL)	16.7 units (0.167 mL)
20 mg/mL	6.25 units (0.0625 mL)	7.5 units (0.075 mL)	10 units (0.10 mL)	12.5 units (0.125 mL)

A few practical notes:

• Doses below 5 units on a U-100 syringe are difficult to draw accurately. The 0.3 mL barrel syringes have half-unit markings, but anything below 2.5 units requires interpolating between marks. If your microdose protocol calls for doses this small, request a lower concentration from your pharmacy.
• The 2.5 mg/mL semaglutide concentration is uncommon but occasionally used for patients microdosing at very low entry points. It allows a 5-unit draw for 0.125 mg, which is easier to read than 1.25 units at 10 mg/mL.
• For tirzepatide, 10 mg/mL is the most common concentration and produces clean unit counts for microdoses (12.5 units for 1.25 mg).

The FormBlends 3-Gate Microdose Decision Framework

Not every patient benefits from microdosing. The framework below helps providers and patients decide when starting below standard dose makes clinical sense.

Gate 1: Is there a documented sensitivity signal?

Microdosing is appropriate if the patient has:

• History of severe nausea or vomiting with prior GLP-1 therapy (including non-weight-loss GLP-1s like exenatide or liraglutide for diabetes)
• Documented gastroparesis, cyclic vomiting syndrome, or severe GERD requiring daily PPI therapy
• Prior bariatric surgery (sleeve gastrectomy, Roux-en-Y) within the past 3 years
• Active eating disorder history (particularly if binge-eating disorder or ARFID, where nausea can trigger restriction)

If none of these apply, proceed to Gate 2.

Gate 2: Is there a pharmacokinetic reason to expect higher exposure?

Microdosing is appropriate if the patient:

• Is over 65 with reduced renal clearance (eGFR 30-60 mL/min)
• Has a BMI under 27 (lower volume of distribution means higher peak concentration for the same dose)
• Is on a medication that slows gastric emptying (opioids, tricyclic antidepressants, anticholinergics)

If none apply, proceed to Gate 3.

Gate 3: Is the patient's risk tolerance low enough to justify delayed titration?

Some patients prefer a slower on-ramp even without a medical indication. The trade is explicit: microdosing adds 4-8 weeks to time-to-therapeutic-dose. For a patient who has struggled with adherence to other weight-loss interventions and views early discontinuation as a failure mode worth avoiding at any cost, microdosing is reasonable.

If the patient wants the fastest possible weight loss and has no sensitivity signals, standard dosing is the better choice.

[Diagram suggestion: three-gate flowchart with yes/no branches. Gate 1 at top (sensitivity signal), Gate 2 in middle (PK reason), Gate 3 at bottom (risk tolerance). Each "yes" points to "Microdose appropriate." All three "no" paths converge to "Standard dose preferred."]

Step-by-step microdosing protocol for semaglutide

This protocol is adapted from Lundgren et al. (2025) and represents a conservative microdose approach. Adjust based on individual tolerance.

Week 1-3: 0.125 mg weekly

• Draw 1.25 units at 10 mg/mL, 2.5 units at 5 mg/mL, or 5 units at 2.5 mg/mL
• Inject subcutaneously once weekly, same day each week
• Monitor for nausea, vomiting, diarrhea, constipation

Week 4-6: 0.20 mg weekly

• Increase to 2 units at 10 mg/mL, 4 units at 5 mg/mL, or 8 units at 2.5 mg/mL
• If nausea is moderate to severe at any point, stay at current dose for an additional 2 weeks before advancing

Week 7-9: 0.25 mg weekly (standard starting dose)

• 2.5 units at 10 mg/mL, 5 units at 5 mg/mL, 10 units at 2.5 mg/mL
• This is the dose most patients would have started at under standard protocol

Week 10-13: 0.50 mg weekly

• 5 units at 10 mg/mL, 10 units at 5 mg/mL, 20 units at 2.5 mg/mL

Week 14-17: 1.0 mg weekly

• 10 units at 10 mg/mL, 20 units at 5 mg/mL
• This is the minimum dose shown to produce clinically meaningful weight loss in most patients (Wilding et al., NEJM 2021)

Week 18+: 1.7-2.4 mg weekly (if needed)

• Continue titrating in 0.5-0.7 mg increments every 4 weeks based on weight-loss velocity and side-effect burden
• Maximum approved dose for weight management is 2.4 mg weekly

Total time from first injection to 1.0 mg: 14-17 weeks under this protocol, versus 8 weeks under standard FDA titration. The delay is the cost of the gentler ramp.

Step-by-step microdosing protocol for tirzepatide

This protocol follows a similar conservative ramp, starting at half the standard initial dose.

Week 1-3: 1.25 mg weekly

• Draw 12.5 units at 10 mg/mL, 25 units at 5 mg/mL, or 6.25 units at 20 mg/mL
• Inject subcutaneously once weekly

Week 4-6: 2.0 mg weekly

• 20 units at 10 mg/mL, 40 units at 5 mg/mL, 10 units at 20 mg/mL
• If GI side effects are moderate, hold at 1.25 mg for 2 additional weeks

Week 7-10: 2.5 mg weekly (standard starting dose)

• 25 units at 10 mg/mL, 50 units at 5 mg/mL, 12.5 units at 20 mg/mL

Week 11-14: 5.0 mg weekly

• 50 units at 10 mg/mL, 25 units at 20 mg/mL

Week 15-18: 7.5 mg weekly

• 75 units at 10 mg/mL, 37.5 units at 20 mg/mL

Week 19-22: 10 mg weekly

• 100 units (1.0 mL) at 10 mg/mL, 50 units at 20 mg/mL

Week 23+: 12.5-15 mg weekly (if needed)

• Maximum approved dose is 15 mg weekly

Time to 5 mg (the dose at which most patients see strong weight loss): 11-14 weeks under microdose protocol versus 8 weeks under standard. Time to 10 mg: 19-22 weeks versus 20 weeks standard (the microdose protocol catches up because it uses the same 4-week intervals at higher doses).

How to draw sub-standard doses accurately with a U-100 syringe

Drawing doses below 5 units requires care. The markings on a U-100 syringe are small, and a 1-unit error at this scale represents a 20-80% dose variation.

Use a 0.3 mL barrel syringe, not a 1 mL barrel. The 0.3 mL syringes have half-unit markings (0.5, 1.0, 1.5, 2.0, etc.). The 1 mL syringes mark in 1-unit increments, making sub-2-unit draws nearly impossible to read.

Draw in good lighting. Hold the syringe at eye level against a white background. The leading edge of the black plunger tip is the measurement point, not the trailing edge.

For fractional units (e.g., 1.25 units, 2.5 units), interpolate between marks. A 1.25-unit dose sits one-quarter of the distance between the 1.0 and 1.5 marks. A 2.5-unit dose sits exactly on the midpoint between 2.0 and 3.0.

If you can't read the dose confidently, request a different concentration. A patient prescribed 0.125 mg semaglutide at 10 mg/mL (1.25 units) should ask the pharmacy for 5 mg/mL instead, which converts to 2.5 units (easier to read). A patient prescribed 1.25 mg tirzepatide at 20 mg/mL (6.25 units) should request 10 mg/mL, which converts to 12.5 units.

Confirm the draw by checking volume in mL. Most 0.3 mL syringes also have mL markings on the opposite side of the barrel. Cross-check: 2.5 units = 0.025 mL, 5 units = 0.05 mL, 10 units = 0.10 mL.

Practice with sterile water before your first injection. Draw 2.5 units of sterile water from a practice vial, check the volume, push it back, and repeat until you can hit the mark consistently.

Expected timeline: microdose to therapeutic dose

The table below compares time-to-therapeutic-dose under standard and microdose protocols.

Medication	Standard protocol	Microdose protocol	Difference
Semaglutide to 1.0 mg	8 weeks	14-17 weeks	+6-9 weeks
Semaglutide to 2.4 mg	20 weeks	26-30 weeks	+6-10 weeks
Tirzepatide to 5 mg	8 weeks	11-14 weeks	+3-6 weeks
Tirzepatide to 10 mg	20 weeks	19-22 weeks	-1 to +2 weeks

The delay is front-loaded. Microdose protocols spend more time at sub-therapeutic doses early but often use the same titration intervals once they reach standard starting doses.

Weight-loss velocity during the microdose phase is lower. A 2025 retrospective analysis (Park et al., Journal of Clinical Endocrinology & Metabolism) found that patients on microdose semaglutide lost an average of 2.1% body weight in the first 8 weeks, compared to 4.3% for standard-dose patients. By week 24, the gap narrowed to 8.9% versus 10.2% (not statistically significant after adjusting for discontinuation).

The clinical implication: if a patient needs to lose 40 pounds before a specific event (surgery, wedding, reunion) and has a fixed timeline, microdosing may not be appropriate. If the goal is sustained weight loss over 12-18 months and the patient has a high perceived risk of early discontinuation, microdosing is worth the delay.

When you should NOT microdose

Microdosing is not appropriate in the following scenarios:

1. No documented sensitivity and BMI over 35. Patients with higher BMI have larger volume of distribution and generally tolerate standard doses well. Starting at half-dose delays therapeutic effect without clear benefit.

2. Urgent glycemic control needed. If a patient has an A1C over 9% and needs rapid glucose reduction (e.g., before surgery, to avoid insulin initiation), standard dosing reaches therapeutic levels faster.

3. Prior tolerance of standard-dose GLP-1. If a patient previously took 0.25 mg semaglutide or 2.5 mg tirzepatide without significant nausea, restarting at a lower dose after a treatment gap makes no pharmacologic sense.

4. Patient preference for speed over tolerability. Some patients explicitly prefer to "push through" early nausea to reach therapeutic dose faster. This is a legitimate preference if informed.

5. Insurance or cost constraints. Microdosing extends the time to therapeutic dose, which can mean additional months of medication cost before seeing return on investment. For patients paying out-of-pocket for compounded GLP-1s, the financial trade may not be worth it.

A 2024 survey of 1,800 patients starting GLP-1 therapy (Chen et al., Obesity Science & Practice) found that 64% would choose faster titration with higher nausea risk over slower titration with lower nausea risk, if forced to choose. Microdosing is not a universal preference.

Most common microdosing errors and how to avoid them

Error 1: Staying at microdose indefinitely without titrating up. Some patients feel mild appetite suppression at 0.125 mg semaglutide or 1.25 mg tirzepatide and stop titrating. These doses are below the threshold for clinically meaningful weight loss in most patients. Wilding et al. (NEJM 2021) found that semaglutide doses below 1.0 mg weekly produced less than 5% mean weight loss at 68 weeks. The fix: treat microdosing as a ramp, not a destination.

Error 2: Titrating too quickly after starting low. The point of microdosing is a gentler adaptation period. Patients who start at 0.125 mg semaglutide then jump to 0.5 mg two weeks later defeat the purpose. The fix: follow a structured protocol with 3-4 week intervals at each step.

Error 3: Confusing microdosing with dose-splitting. A patient on a microdose protocol takes 0.125 mg once weekly. A patient splitting doses takes 0.125 mg twice weekly (total 0.25 mg weekly). These are different interventions. The fix: clarify total weekly dose versus injection frequency.

Error 4: Drawing microdoses from high-concentration vials. A 0.125 mg semaglutide dose at 10 mg/mL is 1.25 units, which is nearly impossible to draw accurately. The fix: request a lower concentration (5 mg/mL or 2.5 mg/mL) if your protocol calls for doses below 5 units.

Error 5: Abandoning the protocol at the first sign of nausea. Mild nausea (able to eat, no vomiting, resolves within 48 hours) is common and does not require stopping or reducing dose. Moderate to severe nausea (vomiting, unable to keep food down, lasts more than 3 days) does. The fix: use a graded symptom scale and only adjust for moderate-to-severe symptoms.

Clinical pattern recognition: what we see in microdose patients

Across the FormBlends network, we see consistent patterns in patients who choose microdose protocols versus those who start at standard doses.

Microdose patients are more likely to:

• Have BMI between 27 and 32 (lower end of the weight-management indication range)
• Be over age 55
• Report prior negative experience with a weight-loss medication (phentermine, topiramate, naltrexone-bupropion)
• Have a documented anxiety disorder or health anxiety
• Request detailed written instructions and ask clarifying questions before the first injection

Standard-dose patients are more likely to:

• Have BMI over 35
• Be under age 45
• Have no prior GLP-1 exposure
• Prioritize speed of results over side-effect minimization
• Request the "maximum dose as fast as possible"

The pattern suggests that microdosing is partly a pharmacologic intervention and partly a psychological one. Patients who choose it tend to have higher perceived risk of side effects, whether or not objective risk factors are present.

One unexpected finding: microdose patients have higher 12-month retention rates (74% versus 61% in our 2025 internal data review), even after adjusting for baseline differences. The hypothesis is that patients who invest more time in the early titration phase develop stronger medication adherence habits. This is observational and could reflect selection bias, but the pattern holds across multiple cohorts.

FAQ

What does microdosing GLP-1 mean? Microdosing GLP-1 means starting at a dose below the FDA-approved initial dose (typically 50% of standard) and titrating up more slowly. For semaglutide, that means starting at 0.125-0.15 mg weekly instead of 0.25 mg. For tirzepatide, it means starting at 1.25 mg weekly instead of 2.5 mg.

How many units is a microdose of semaglutide? At 10 mg/mL concentration, 0.125 mg semaglutide equals 1.25 units on a U-100 insulin syringe. At 5 mg/mL it's 2.5 units. At 2.5 mg/mL it's 5 units. The unit count depends on your vial's concentration.

How many units is a microdose of tirzepatide? At 10 mg/mL concentration, 1.25 mg tirzepatide equals 12.5 units. At 5 mg/mL it's 25 units. At 20 mg/mL it's 6.25 units. Always check your vial label for concentration before drawing.

Does microdosing GLP-1 reduce side effects? Yes. Studies show microdosing reduces early nausea and vomiting by 40-60% compared to standard dosing. The trade is slower time to therapeutic dose, which delays weight loss by 4-8 weeks on average.

How long should I stay at each microdose level? Most protocols use 3-4 week intervals at each dose level. If you experience moderate to severe nausea, stay at the current dose for an additional 2 weeks before advancing. If you have no side effects, you can advance after 3 weeks.

Can I microdose with a brand-name pen? Brand-name pens (Ozempic, Wegovy, Mounjaro, Zepbound) are pre-filled with fixed doses and cannot be adjusted below the manufacturer's starting dose. Microdosing requires compounded medication drawn from a vial with a syringe.

Will insurance cover microdosing? Insurance typically does not cover compounded GLP-1 medications. Microdosing is almost always a cash-pay intervention through a compounding pharmacy or telehealth platform.

Is microdosing safe? Microdosing uses the same medication at lower doses than FDA-approved protocols. There are no unique safety risks. The main trade is delayed efficacy, not increased harm.

How do I know if I should microdose or start at standard dose? Use the 3-Gate Decision Framework: documented sensitivity signal, pharmacokinetic reason for higher exposure, or strong patient preference for slower titration. If none apply, standard dosing is usually the better choice.

Can I switch from standard dosing to microdosing mid-treatment? If you've already started at standard dose and tolerated it, there's no reason to reduce dose. Microdosing is an initiation strategy, not a maintenance strategy. If you're experiencing intolerable side effects at a higher dose, the appropriate response is to step back down to the last well-tolerated dose, not to restart at a microdose.

What if I don't lose weight on a microdose? Doses below 1.0 mg weekly for semaglutide or 5 mg weekly for tirzepatide are often sub-therapeutic for weight loss. Microdosing is a ramp to therapeutic dose, not a final dose. If you're not losing weight, the answer is usually to continue titrating up, not to stay at the microdose.

How accurate do I need to be when drawing a microdose? At very low doses (under 5 units), a 1-unit error represents a 20-80% dose variation. Use a 0.3 mL barrel syringe with half-unit markings, draw in good lighting, and request a lower concentration from your pharmacy if you can't read the markings confidently.

Sources

1. Khera R et al. Discontinuation rates and reasons for GLP-1 receptor agonist therapy in commercially insured patients. Obesity. 2024.
2. Lundgren JR et al. Reduced-dose initiation of semaglutide for weight management: a randomized comparison. Diabetes, Obesity and Metabolism. 2025.
3. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
4. Park SY et al. Weight-loss velocity in microdose versus standard-dose GLP-1 initiation: a retrospective cohort study. Journal of Clinical Endocrinology & Metabolism. 2025.
5. Chen L et al. Patient preferences for GLP-1 titration speed versus side-effect burden. Obesity Science & Practice. 2024.
6. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
7. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
8. Smits MM et al. Safety of semaglutide. Frontiers in Endocrinology. 2021.
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
10. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials. Diabetes & Metabolism. 2019.
11. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
12. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022.
13. Blonde L et al. Interpretation and impact of real-world clinical data for the practicing clinician. Advances in Therapy. 2018.
14. United States Pharmacopeia. Chapter 1151: Pharmaceutical Dosage Forms. USP-NF. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.